Market Research Logo

Transforming Growth Factor Beta 1 (TGFB1) - Pipeline Review, H2 2016

Transforming Growth Factor Beta 1 (TGFB1) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Transforming Growth Factor Beta 1 (TGFB1) - Pipeline Review, H2 2016’, provides in depth analysis on Transforming Growth Factor Beta 1 (TGFB1) targeted pipeline therapeutics.

The report provides comprehensive information on the Transforming Growth Factor Beta 1 (TGFB1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Transforming Growth Factor Beta 1 (TGFB1)
  • The report reviews Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Transforming Growth Factor Beta 1 (TGFB1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Transforming Growth Factor Beta 1 (TGFB1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Transforming Growth Factor Beta 1 (TGFB1) Overview
Therapeutics Development
Transforming Growth Factor Beta 1 (TGFB1) - Products under Development by Stage of Development
Transforming Growth Factor Beta 1 (TGFB1) - Products under Development by Therapy Area
Transforming Growth Factor Beta 1 (TGFB1) - Products under Development by Indication
Transforming Growth Factor Beta 1 (TGFB1) - Pipeline Products Glance
Late Stage Products
Early Stage Products
Transforming Growth Factor Beta 1 (TGFB1) - Products under Development by Companies
Transforming Growth Factor Beta 1 (TGFB1) - Products under Development by Universities/Institutes
Transforming Growth Factor Beta 1 (TGFB1) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Transforming Growth Factor Beta 1 (TGFB1) - Companies Involved in Therapeutics Development
Acceleron Pharma, Inc.
Digna Biotech, S.L.
Dong Wha Pharma Co., Ltd.
Eli Lilly and Company
Huabo Biopharm Co., Ltd.
Isarna Therapeutics GmbH
Johnson & Johnson
Novartis AG
Scholar Rock, Inc.
Sirnaomics, Inc.
Taisho Pharmaceutical Holdings Co., Ltd.
TissueGene, Inc.
Transforming Growth Factor Beta 1 (TGFB1) - Drug Profiles
ACE-1332 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibody to Inhibit TGF-Beta 1 for Osteoarthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibody to Inhibit TGFB1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
decorin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
disitertide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DW-1029M - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HB-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HB-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ISTH-1047 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ISTH-1106 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
melittin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit TGF Beta 1 for Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Activate TGF beta1 for Autoimmune Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit TGF Beta1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit TGF-Beta-1 for Acute Pain and Chronic Pancreatitis Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STP-705 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TASP-0382088 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tonogenchoncel-L - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XOMA-089 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Transforming Growth Factor Beta 1 (TGFB1) - Dormant Projects
Transforming Growth Factor Beta 1 (TGFB1) - Discontinued Products
Transforming Growth Factor Beta 1 (TGFB1) - Featured News & Press Releases
Feb 16, 2016: Regenerative Medicine Company, TissueGene, adds Dr. Gurdyal Kalsi as Chief Medical Officer
Jul 14, 2015: Scholar Rock Presents Preclinical Data for First Demonstration of Novel Pharmacological Approach to Targeting the TGFß1 Latent Complex
May 11, 2015: TissueGene Presents Phase 2 Data for Its Novel Cell Therapy for the Treatment of Osteoarthritis of the Knee
Jan 22, 2015: Sirnaomics Files to Begin Trial of Scar-healing Drug in China as it Seeks Funding in US
Jan 05, 2015: Sirnaomics and Partner Submit IND to CFDA
Nov 17, 2014: TissueGene Receives Recommendations from FDA on Pathway to Phase 3 Trial of TG-C for Treatment of Osteoarthritis of the Knee
Nov 14, 2012: TissueGene Completes Enrollment In US Phase II Study Of TG-C In Patients With Knee Osteoarthritis
Jun 28, 2012: Sirnaomics Nears Phase I Study of Wound-Healing Drug as It Eyes the microRNA Field
Jun 25, 2012: Sirnaomics Receives NIH SBIR Grant For Developing siRNA Therapeutic Product STP705
May 19, 2011: TissueGene Initiates Patient Enrollment For Phase II Study Of TG-C For Osteoarthritis Of Knee
Mar 25, 2010: Digna Biotech Announced The Results Of Disitertide Proof Of Concept Trial In The Topical Treatment Of Skin Fibrosis
Mar 03, 2009: TissueGene Announces Regulatory Allowance To Initiate Phase IIa Study Of TG-C In South Korea For Osteoarthritis Of The Knee
Oct 19, 2007: Digna Biotech Biotechnological Company and Isdin Laboratory Begin Phase II Of A Product For Scleroderma
Jul 24, 2006: TissueGene Initiates Phase I Clinical Trial with TG-C
Apr 19, 2005: RheoGene Inc. And TissueGene Inc. Sign Collaborative Agreement For Bone Regeneration And Repair Program
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Indication, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Number of Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Pipeline by Acceleron Pharma, Inc., H2 2016
Pipeline by Digna Biotech, S.L., H2 2016
Pipeline by Dong Wha Pharma Co., Ltd., H2 2016
Pipeline by Eli Lilly and Company, H2 2016
Pipeline by Huabo Biopharm Co., Ltd., H2 2016
Pipeline by Isarna Therapeutics GmbH, H2 2016
Pipeline by Johnson & Johnson, H2 2016
Pipeline by Novartis AG, H2 2016
Pipeline by Scholar Rock, Inc., H2 2016
Pipeline by Sirnaomics, Inc., H2 2016
Pipeline by Taisho Pharmaceutical Holdings Co., Ltd., H2 2016
Pipeline by TissueGene, Inc., H2 2016
Dormant Projects, H2 2016
Dormant Projects (Contd..1), H2 2016
Dormant Projects (Contd..2), H2 2016
Discontinued Products, H2 2016
List of Figures
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Top 10 Indication, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Type, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report